Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

Max Gelman

Senior Editor

Arvinas CEO John Houston is planning to retire after more than eight years at the helm, the company announced Wednesday, as its lead protein degrader …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

Max Gelman

Senior Editor

Sign up to read this article for free.

Who pays the most in biopharma? We analyzed median pay at 177 companies

Federal judge sides with FDA on its mifepristone safety program

Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025

Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays

AstraZeneca’s Alexion inks AAV capsid deal with JCR Pharma

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Q&A: Re­tir­ing Arv­inas CEO John Hous­ton talks PRO­TACs, in­vestor con­fi­dence and what’s next with Pfiz­er

Max Gelman

Senior Editor

Sign up to read this article for free.

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Fed­er­al judge sides with FDA on its mifepri­s­tone safe­ty pro­gram

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

As­traZeneca’s Alex­ion inks AAV cap­sid deal with JCR Phar­ma

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

Who pays the most in biopharma? We analyzed median pay at 177 companies

Federal judge sides with FDA on its mifepristone safety program

Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025

Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays

AstraZeneca’s Alexion inks AAV capsid deal with JCR Pharma

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases